GlassScriptPhysician profile
Hlee Lor
NPI 1639804818
$6,643.24
in general payments reported to CMS, 2019-2025
37 companies · $4,160 in 2025
The $4,160 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $691 · 2024: $1,793 · 2025: $4,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,643.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $837.80 | 2024-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $588.00 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $524.58 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $410.79 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $366.84 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Genzyme Corporation | $347.28 | 2024-2025 | |
| Mannkind Corporation | $313.91 | 2023-2025 | Afrezza |
| Corcept Therapeutics | $307.29 | 2024-2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $271.14 | 2023-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $227.50 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $201.99 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Regeneron Healthcare Solutions, INC. | $200.62 | 2024-2025 | Dupixent |
| Medtronic, INC. | $193.51 | 2024-2025 | Minimed 780g |
| Glaxosmithkline, LLC. | $192.58 | 2023-2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.67 | 2024-2025 | Jardiance |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $153.74 | 2025 | Teriparatide |
| Antares Pharma, INC. | $129.31 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $116.95 | 2025 | |
| Intra-Sana Laboratories | $113.42 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Dexcom, INC. | $110.42 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $93.65 | 2025 | Tezspire, Fasenra |
| Radius Health, INC. | $90.38 | 2023-2025 | Tymlos |
| Beta Bionics, INC. | $88.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Madrigal Pharmaceuticals | $84.52 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $83.10 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $58.95 | 2025 | Twiist |
| Takeda Pharmaceuticals U.S.A., INC. | $50.71 | 2025 | Cuvitru |
| Inspire Medical Systems, INC. | $49.74 | 2023 | Inspire |
| Abbott Laboratories | $49.72 | 2025 | Freestyle Libre 3 |
| Verity Pharmaceuticals INC. | $37.79 | 2024-2025 | Tlando |
| Tolmar, INC. | $29.41 | 2025 | Jatenzo |
| Kyowa Kirin, INC. | $27.95 | 2024 | Crysvita |
| Pfizer INC. | $27.35 | 2025 | |
| Alvogen INC | $25.81 | 2023 | Teriparatide |
| Insulet Corporation | $23.39 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $23.22 | 2025 | |
| Cequr Corporation | $19.60 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hlee Lor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.